Sept 14 ( ) - Drug developer Electra Therapeutics is targeting a valuation of up to $977.6 million in its U.S. initial public offering, according to a filing on Monday, extending a comeback in biotech listings this year. The South San Francisco, California-based company is seeking to raise as much as $346.7 million by offering about 21.67 million shares priced between $14 and $16 apiece. • The listing comes as the typically busy fall IPO window has been slower than last year due to macroeconomic uncertainty and market volatility, although biotech offerings have broadly rebounded. • Electra Therapeutics, a late-clinical-stage biotech company, develops therapies that target signal regulatory proteins to treat immunological diseases and cancer. • Its lead experimental drug, ipsoprubart, targets harmful immune cells involved in secondary hemophagocytic lymphohistiocytosis, a severe condition that causes the immune system to become dangerously overactive. The drug is being tested in a global study intended to support approval. • Electra plans to use the IPO proceeds to fund clinical trials for ipsoprubart, advance its second drug candidate, ELA822, and support its working capital and other corporate needs. • The company plans to list its shares on Nasdaq under the symbol "ETRA." • Jefferies, TD Cowen, Evercore ISI and Cantor are the underwriters for the offering. (Reporting by Pragyan Kalita in Bengaluru; Editing by Shreya Biswas)
Extract — continue reading at the source.
